Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-11-06 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
监事会关于拟认定核心员工的核查意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board regarding the verification and approval of the nomination of core employees by the company's board. It references internal governance procedures, compliance with listing rules, and employee notification processes. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management-related personnel matters, specifically the recognition of core employees, which aligns with management or board information disclosures. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification, so RNS or RPA are less appropriate.
2022-11-06 Chinese
第三届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the convening and attendance of the meeting, the agenda items discussed, voting results, and mentions that the proposals do not require shareholder meeting approval. The content focuses on internal supervisory board decisions and approvals related to employee stock incentive plans and core employee identification. There is no indication of financial statements, audit reports, or regulatory filings. It is not a full annual or interim report, nor a call transcript or capital update. The document is an official announcement of board/management decisions, specifically from the supervisory board, which falls under Board/Management Information (MANG). The document length is short and contains detailed meeting resolutions, not just a notice or announcement of a report, so it is not RPA or RNS.
2022-11-06 Chinese
监事会关于2022年股权激励计划授予激励对象的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the 2022 equity incentive plan's granted incentive recipients. It discusses compliance with relevant laws and regulations, the process of public disclosure, and the qualifications of the incentive recipients. There is no financial data, no earnings or annual report content, no voting results, no management changes, no legal proceedings, no capital changes, and no mention of report publication or certification. The document is a regulatory announcement related to compliance and internal governance regarding the equity incentive plan. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) as a general compliance announcement that does not fit other specific categories.
2022-11-06 Chinese
第三届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the approval of the company's 2022 third quarter report. It includes details about the meeting, attendance, and the Supervisory Board's review and approval of the quarterly report. The document does not contain the actual financial statements or substantive financial data of the quarterly report itself, but rather the announcement of the meeting resolution approving the report. The document length is short (1042 characters), and it serves as an official announcement of the Supervisory Board's decision rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to the quarterly report approval, not the Interim/Quarterly Report (IR) itself.
2022-10-27 Chinese
第三届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the convening and attendance of the third board's sixth meeting, including the approval of the 2022 third quarter report. The document does not contain the actual financial data or the full quarterly report but references that the 2022 third quarter report was disclosed on the Beijing Stock Exchange website. The document is primarily an announcement of the board meeting decisions and resolutions, not the report itself. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and decisions.
2022-10-27 Chinese
2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京三元基因药业股份有限公司 2022 年第三季度报告" which translates to "Beijing Sanyuan Gene Pharmaceutical Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial data for the quarter ending September 30, 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and management discussion of financial results. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.